Related references
Note: Only part of the references are listed.Expanding Indications for Liver Transplant: Tumor and Patient Factors
Kevin Ka-Wan Chu et al.
GUT AND LIVER (2021)
Systematic review with meta-analysis: sirolimus-or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma
Sam E. Grigg et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study
Tsuyoshi Shimamura et al.
TRANSPLANT INTERNATIONAL (2019)
Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study
Long-Bin Jeng et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better
Vincenzo Mazzaferro et al.
HEPATOLOGY (2018)
Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry
Hans-Christian Pommergaard et al.
HPB (2018)
Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions
Mihai-Calin Pavel et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Promise and Pitfalls of Using a-Fetoprotein in Liver Transplantation Allocation for Hepatocellular Carcinoma
Barry Schlansky et al.
JAMA SURGERY (2017)
n Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
Hallvard Holdaas et al.
JOURNAL OF TRANSPLANTATION (2016)
Everolimus and sirolimus in transplantation-related but different
Jost Klawitter et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review
Nicola de'Angelis et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Everolimus Inhibits Anti-HLA I Antibody-Mediated Endothelial Cell Signaling, Migration and Proliferation More Potently Than Sirolimus
Y. -P. Jin et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
P. De Simone et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Sirolimus-Based Immunosuppression Is Associated with Increased Survival After Liver Transplantation for Hepatocellular Carcinoma
Christian Toso et al.
HEPATOLOGY (2010)
Conversion from a Calcineurin Inhibitor to Everolimus Therapy in Maintenance Liver Transplant Recipients: A Prospective, Randomized, Multicenter Trial
Paolo De Simone et al.
LIVER TRANSPLANTATION (2009)
Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients
Richard J. Knight et al.
CLINICAL TRANSPLANTATION (2007)
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects
Christian Toso et al.
TRANSPLANTATION (2007)
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma
David Semela et al.
JOURNAL OF HEPATOLOGY (2007)
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma:: A multicenter study of 412 patients
Thomas Decaens et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Immunosuppression: Evolution in practice and trends, 1994-2004
HU Meier-Kriesche et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression
M Vivarelli et al.
LIVER TRANSPLANTATION (2005)
Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation
S Tamura et al.
ARCHIVES OF SURGERY (2001)
Share Paper
